A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts

Blood

Volumn 98, Issue 8, 2001, Pages 2535-2543

  Press, Oliver W ^a,b   Corcoran, Melissa ^a   Subbiah, Krishnan ^a   Hamlin, Don K ^a   Scott Wilbur, D ^a   Johnson, Timothy ^a   Theodore, Louis ^a   Yau, Eric ^a   Mallett, Robert ^a   Meyer, Damon L ^a   Axworthy, Don ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; STREPTAVIDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; RELAPSE; XENOGRAFT;

EID: 0035889126     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.8.2535     Document Type: Article

References (42)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000; 50:7-33.
2. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
3. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1 F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584-591.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
5. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
6. Tedder TF, Engel P. CD20: a regulator of cellcycle progression of B lymphocytes. Immunol Today. 1994;15:450-454.
7. Press OW, Howell-Clark J, Anderson S, Bernstein I, Retention of B-cell-specific monoclonal antibodies by human lymphoma cells, Blood. 1994;83:1390-1397.
8. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 1989;49:4906-4912.
9. Kaminski MS, Estes J, Zasadny KR, et al. Radio-immunotherapy with iodine (131)1 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 2000;96:1259-1266.
10. Kaminski MS, Estes J, Regan D. Front-line treatment of advanced B cell low-grade lymphoma with radiolabeled anti-B1 antibody: initial experience [abstract]. Proc Am Soc Clin Oncol. 1997; 16:15a.
11. Kaminski M, Zelenetz A, Press O. Multicenter phase III study of iodine-131-tositumomab (anti-B1 antibody) for chemotherapy-refractory low grade or transformed low grade non-Hodgkin's lymphoma [abstract]. Blood. 1998;92:316a.
12. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
13. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
14. Witzig TE, White CA, Gordon LI, et al. Final results of a randomized controlled study of the Zevalin™ radloimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL [abstract]. Blood. 2000;96:831 a.
15. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
16. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131 I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
17. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131 - labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-3278.
18. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942,
19. Wilbur DS, Pathare PM, Hamlin DK, et al. Development of new biotin/streptavidin reagents for pretargeting. Biomol Eng. 1999;16:113-118.
20. Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999;14:153-166.
21. Paganelli G, Riva P, Deleide G, et al. In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int J Cancer Suppl. 1988;2:121- 125.
22. Goodwin DA, Meares CF, Osen M. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. J Nucl Med. 1998;39:1813-1818.
23. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294-1302.
24. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A. 2000; 97:1802-1807.
25. Schultz J, Lin Y, Sanderson J, et al. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 2000;60:6663-6669.
26. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer, Clin Cancer Res. 2000;6:406-414.
27. Paganelli G, Grana C, Chinol M, et al. Antibodyguided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nuc Med. 1999;26:348-357.
28. Gautherot E, Rouvier E, Daniel I., et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131l-labeled bivalent hapten, J Nucl Med. 2000;41:480-487.
29. Paganelli G, Orecchia R, Jereczek-Fossa B, et al. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur J Nucl Med. 1998;25:1336-1339.
30. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res. 1991;51:676-681.
31. Hylarides MD, Mallet R, Meyer DL. A robust method for the preparation and purification of antibody/streptavidin conjugates. Bioconjug Chem. 2001;12:421-427.
32. Janolino VG, Fontecha J, Swaisgood HE. A spectrophotometric assay for biotin-binding sites of immobilized avidin. Appl Biochem Biotech. 1996; 56:1 -7.
33. 131l-anti-CD45 antibody in congenic and H2-mismatched murine transplant models. Blood. 1999;93:737-745.
34. Mirzadeh S, Brechbiel MW, Atcher RW, Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl) diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjug Chem. 1990;1:59-65.
35. Theodore LJ, Axworthy DB, Reno JM. Small molecular weight ligand hexose containing clearing agents. US patent 6 075 010. June 13, 2000.
36. Theodore LJ, Axworthy DB. Cluster clearing agents. US patent 6 172 045. January 9, 2001.
37. Axworthy DB, Theodore LJ, Gustavson LM, Reno JM. Biotinidase resistant biotin-DOTA conjugates. US patent 5 955 605. September 21, 1999.
38. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
39. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase 1/11 study results. Cancer Biother Radiopharm. 2000; 15:15-29.
40. Saga T, Weinstein JN, Jeong JM, et al. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res. 1994;54:2160-2165.
41. Rusckowski M, Fogarasi M, Fritz B, Hnatowich DJ. Effect of endogenous biotin on the applications of streptavidin and biotin in mice. Nucl Med Biol. 1997;24:263-268.
42. DeNardo SJ, DeNardo GL, DeNardo DG, et al. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. Clin Cancer Res. 1999;5:3213s-3218s.